Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2020.106088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Authors' response to "Comment on 'Getting midwives back to hospitals: A discrete choice experiment'".
Int J Nurs Stud
December 2024
WHU Otto-Beisheim School of Management, Germany. Electronic address:
Response Regarding: Adenosine 2A Receptor Agonism Improves Survival in Extracorporeal Cardiopulmonary Resuscitation.
J Surg Res
December 2024
Department of Surgery, University of Virginia Health System, 1215 Lee Street, Charlottesville, Virginia. Electronic address:
FIGIJ and NASPAG Response to Dr. Grover's letter to the editor.
J Pediatr Adolesc Gynecol
December 2024
North American Society Pediatric Adolescent Gynecology, Division Director Pediatric Adolescent Gynecology, Department of Obstetrics, Gynecology and Reproductive Sciences, Courtesy Appointment Department of Pediatrics, 1120 NW 14th Street, Miami, Florida 33136. Electronic address:
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.
Hematol Oncol
January 2025
Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFThe lysine-specific demethylase 5 (KDM5) family, a key post-translational modification of chromatin, can shape tumor immune microenvironment. Here, we performed an extensive clinical and bioinformatic analysis to explore the association between KDM5 mutation and tumor immunity and its impact on the outcomes in pan-cancer immunotherapy. In 2943 patients across 12 tumor types treated with immune checkpoint inhibitors, KDM5-mutant tumors were associated with favorable overall survival (hazard ratio, 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!